|
|
||||||||
1 State Research Center for Applied Microbiology and Biotechnology, Obolensk 142279, Moscow Region, Russia
2 Russian Research Anti-Plague Institute Microbe, Saratov 410071, Russia
3 N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow 119991, Russia
4 Research Center Borstel, Leibniz Center for Medicine and Biosciences, D-23845 Borstel, Germany
5 Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston MA 02115, USA
Correspondence
Andrey P. Anisimov
anisimov{at}obolensk.org
Received 8 August 2006
Accepted 12 December 2006
lpxM mutants were then examined in a mouse model. The
lpxM mutation in a virulent strain led to no change in the LD50 value compared to that of the parental strain, while the
lpxM mutation in attenuated strains led to a modest 2.516-fold reduction in virulence. LPS preparations containing fully hexa-acylated lipid A were ten times more toxic in actinomycin D-treated mice then preparations lacking this lipid A isoform, although this was not significant (P>0.05). The
lpxM mutation in vaccine strain EV caused a significant increase in its protective potency. These studies suggest there is little impact from lipid A modifications on the virulence of Y. pestis strains but there are potential improvements in the protective properties in attenuated vaccine strains.
Abbreviations: CI, 95 % confidence interval; ESI FT-ICR, electrospray ionization Fourier transform ion cyclotron resonance; ImD50, 50 % immunizing dose; LAhexa, hexa-acyl lipid A; LAtetra, tetra-acyl lipid A; LPS, lipopolysaccharide.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | J MED MICROBIOL | MICROBIOLOGY | J GEN VIROL | ALL SGM JOURNALS |